

Cadila Healthcare Limited


Investor Presentation

November 2017



A Leading Pharmaceutical Company







- 2. IMS Health, IMS National Prescription Audit, MAT September 2017
- 3. For the year ending March 31, 2017
- 4. As of November 9, 2017
- 5. US\$ 1 = INR 64.5

Vertically Integrated Business Model with Presence Across The Pharma Value Chain



APIs	Generics and Niche Generics	Specialty and Branded Business ⁽¹⁾	Biologics and Vaccines	NCEs
 Selective backward integration Niche API supply to key clients 215+ scientists 130 active DMFs filed with USFDA ² 	 Increased focus on niche categories (Transdermal, Nasals, Modified Release Oral Solids, Topicals etc.) 725+ scientists Total 316 ANDAs filed (as of Sep 30, 2017) 85+ para IV filings Generating >85% revenues from formulations business across India, U.S. and other markets 	 Focus on pain management, dermatology and oncology products Development of 505(b)(2) opportunities Received USFDA approval for first 505(b)(2) filing viz. Pitavastatin Magnesium tablets Acquisition of Sentynl Therapeutics Inc., specializing in pain management 	 Biologics: 18 biosimilars (pipeline and launched) and 7 novel products (pipeline) ² 9 launched in India; 4 in Emerging Markets Exemptia[™] (biosimilar of Adalimumab) in India 100+ scientists, Vaccines: 19 under development (including 6 where marketing authorization has been received) 4 vaccines launched ~ 50 scientists Dedicated, separate facilities for biologics and vaccines 	 NCEs: 3 NCEs (2 new and 1 existing for new indications) 1st NCE in India developed in-house by the company: Lipaglyn® (Saroglitazar) Phase II trials going on in US for 3 indications of Lipaglyn® 270+ scientists Strong scientific advisory board Dedicated research facility



Key Business Segments






	Key Formulations Businesses	Other Businesses & Alliances	Emerging Businesses
Divisions	 India formulations #4 by value¹ 4.3% market share ¹ US formulations #9 by prescription volumes² 2.89% market share ² Latin America Emerging Markets of Asia and Africa 	 EU Formulations Consumer Wellness Animal Health APIs JVs & alliances 	BiologicsVaccinesNCEs
Key Themes	 Sustainable and profitable growth Significant revenue contribution 	Growth potential in Wellness and Animal Health segments	 Innovative technology with high entry barriers for competition
In-House Capabilities serving as bedrock of organization	32 manufacturing facilities across India, US, Brazil and Germany Manufacturing	8 R&D sites across India, US and Italy 1350+ scientists R&D Capabilities	Highly experienced and qualified management team People



Track Record of Value Creation







- 1. FY07 and FY12 financials as per IGAAP; FY17 financials as per IND AS and hence not comparable
- 2. US\$ 1 = 64.5
- 3. Market capitalization is calculated by applying the closing price of the financial year

4. As of November 9, 2017



Key Business Segments






Our US Formulations Business

- #9 generics player in US (based on prescriptions) with a market share of 2.89%¹
 - Among top 3 players by prescription in all of top 10 products marketed in the US (Source: IMS Health, IMS National Sales Perspective Audit, MAT September 2017 and IMS National Prescription Audit, September 2017)
- Sale of generic oral solids and injectable products; 95+ products commercialized
 - Recently launched generic version of Lialda® (Mesalamine Delayed Release 1.2 g)
- Strong product pipeline
 - 157 ANDAs pending approval (of which 65 Para IV filings)
- Cost efficient manufacturing and supply chain
- Relationships with key wholesalers and retail pharmacy chains
- Acquired Sentynl Therapeutics Inc., a US based specialty pharmaceutical company, specializing in pain management segment in Fiscal 2017

Our US Formulation Sales





Gross Sales, US\$ MM

Strong Filing Track Record and Addition to Capabilities



Growing Focus on Complex Generics Business







Large ANDA Pipeline With Increasing Focus on **Niche Filings**



Approved ANDAs by Type

Nasals

1

As on 30 September 2017

Injectables

8

Oral

Suspension-

1

Orals -

Controlled

Substance

6

Orals -


Modified

Release

32



As on 30 September 2017



Topicals


4



Strong Leadership in India Formulations Business



Leading Player in the \$18 Bn Market of India¹






- 1. Source: AWACS MAT September 2017
- 2. FY15 financials as per IGAAP; FY16 and FY17 financials as per IND AS
- 3. Excludes ~1,400 managers
- Excludes ~1,400 r
 US\$ 1 = INR 64.5
- 5. Source: AWACS

Focus on Key Therapeutic Areas in India





Leadership positions (top 3) in Gynaecology, Respiratory, Pain Management, Cardiovascular and Dermatology

Trademark acquisitions to fill the portfolio gaps – recently acquired trademarks from MSD in men's and women's health

Introduction of biologicals and vaccines products

In-licensing arrangements

Improving field force productivity



Represents Zydus' ranking in the promoted covered market

Other Growing Formulations Markets




Latin America		Emerging Markets	
			Emerging Ma
Zydus Size ²	c.US\$ 38 MM	Zydus Size ²	(
Zydus Growth	~12%	Zydus Growth	
 Two large pharmace. 	utical markets in Latin America	 Branded generics and g 	generic generi
 Branded generics and 	d generic generics	 One of the leading com 	panies in seve
• Brazil: 85+ filings, 45	approvals, 40+ products being sold	 Launched 4 biosimilars 	
 Mexico: 40+ filings, 3 commercialized 	35+ approvals, 20+ products	 Continue to expand geo markets 	ographical pre
· · ·	Branded) – CVS, central nervous system, epatology and nutraceuticals	 Leveraging existing por markets 	tfolio of India a

Emerging Markets	
	Emerging Markets in Asia and Africa
Zydus Size ²	c.US\$ 78 MM
Zydus Growth	~6%
Branded generics anOne of the leading comparison	nd generic generics ompanies in several of these markets
Launched 4 biosimila	ars
 Continue to expand a markets 	geographical presence in select emerging
 Leveraging existing provide the second second	portfolio of India and other regulated



Other Businesses









Value Creation Through Win-win Alliances and Be a Partner of Choice

Zydus Takeda JV

- 50:50 JV with Takeda Pharmaceuticals
- Currently manufacturing complex high-end APIs of Takeda
- Commercial supply of 10 products

Zydus Hospira JV

- 50:50 contract manufacturing JV with Hospira¹ for cytotoxic injectable products
- State-of-the-art cytotoxic facility which is inspected by leading authorities like MHRA, USFDA, TGA etc.
- Manufactured ~17 products which are sold primarily in US and EU

Bayer Zydus JV

- 50:50 JV with Bayer
- Operates in female healthcare, metabolic disorders, diagnostics, CVS, anti-diabetics and oncology segments in India
- Leveraging strengths of Bayer's optimised product portfolio and Zydus' marketing and distribution capabilities
- JV scope covers launch of innovator products of Bayer in India

Other Alliances

- 26 ANDAs filed, 17 approved (for partners)
- Out-licensing deal with Abbott for supply of 24 products (with an option to include 39 additional products)
- Out-licensing and distribution arrangements for biosimilars in certain emerging markets like Turkey, Russia, Indonesia and Columbia





Manufacturing and Innovation



Strong Base of Cost Efficient and State-of-the-Art Manufacturing Facilities





17 facilities for formulations, 4 for API, 3 for vaccines, 3 for biologics, 3 for consumer wellness and 2 for animal health

Capabilities across platforms - Oral Solids, Controlled Substances, Injectables, Topicals, Lyophilized Injectable, Sprays and Transdermals


Focus on quality, efficiency and regulatory compliance



Key Focus Areas for R&D



R&D expenditure formed ~8%¹ of total operating revenues





Capabilities in Complex Segments



Biologics

- 18 biosimilars (pipeline and launched) and 7 novel products (pipeline)
 - Launched 9 products in India and 4 in Emerging Markets
 - Launched Exemptia[™] (biosimilar of Adalimumab) – 1st company in India¹
 - 3 products already in clinical development phase
 - Completed clinical trials for 1 product and applied for marketing authorization In India
 - Development of RabiMabs in collaboration with WHO
- Wide range of indications covered including oncology, nephrology, ophthalmology, infectious diseases, osteoporosis, inflammation

Vaccines

- Launched 4 products, received marketing authorizations for 6 other
 - First Indian company to launch indigenously developed and manufactured H1N1 vaccine – VaxiFlu-S¹
- 19 under development (including 6 where marketing authorization has been received)

NCEs

- Launched Lipaglyn[®] 1st NCE developed by the company, for 2 indications (Diabetic Dyslipidemia and Hypertriglyceridemia)
 - Phase III trials ongoing in India for 3 indications (Lipodystrophy, NASH², Type 2 Diabetes)
 - Phase II trials ongoing in US for 3 indications (NASH², PBC³ and Hypertriglyceridemia)
- 2 other NCE molecules under various stages of development
 - ZYH7 (Dyslipidemia)
 - ZYAN1 (Anemia)






Key Financials




Strong Financial Profile












Leverage (Net Debt / EBITDA)²





1. US\$1 = INR 64.5

2. FY15 financials as per IGAAP; FY16 and FY17 financials as per INDAS and hence not comparable

3. ROE = PAT / average of opening and closing net worth; ROCE = (Profit after tax + Finance cost net of tax) / average of opening and closing (net worth + gross debt)

Key Financial Numbers – Q2 FY18



Consolidated (US\$ Mio.) ¹	Amount	Gr.%	Reve
Total Income from Operations	498	34.6%	
EBIDTA	132	67.5%	Well
EBIDTA % to Total Income from Ops.	26.5%		LatAM ^{4%} Formulations 2%
Profit before tax	110	63.9%	EU Formulations 2%
PBT % to Total Income from Ops.	22.0%		
Net Profit	77	32.5%	
Net Profit % to Total Income from Ops.	15.6%		EM Formulations 4%
R&D Spend % to Total Income from Ops.	8.5%		
Debt net of cash (as at 30-Sep-17)	621		India Formulation
Capex (H1 2017-18)	78		28%



Strategies For The Future







Building Blocks For Our Strategy



Regulatory Compliance and Quality	 Focus on best in class manufacturing People training QUEST: Quality Excellence by Sustainable Transformation; Institutionalising a Culture of Quality
Operational Excellence	 PRISM – cost optimization program adopted in 2002 and institutionalised across the group SLIM - a Strategic, Lean and Integrated Manufacturing initiative
Innovate For Growth	 Continue to replenish generic pipeline in the US with profitable opportunities – move towards specialty In the branded generics / specialty markets of India and other emerging market to focus on additional growth from more advanced areas like biologics Continue to invest behind, innovate and commercialize opportunities in biologics, vaccines and NCEs Near term focus on emerging markets with longer term potential in developed markets
M&A	 Selective M&A Complimentary generic assets or technology platforms Specialty or branded assets Consolidation / leadership





Thank You

DISCLAIMER AND SAFE HARBOUR STATEMENT

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.

